Filtered By:
Management: Hospitals
Vaccination: Ebola Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 39 results found since Jan 2013.
Uganda Reports Worrisome Increase in Ebola Cases in Capital
KAMPALA, Uganda — Ugandan officials have reported 11 more cases of Ebola in the capital since Friday, a worrisome increase in infections just over a month after an outbreak was declared in a remote part of the East African country.
Nine more people in the Kampala metropolitan area tested positive for Ebola on Sunday, in addition to two others on Friday, Health Minister Jane Ruth Aceng said Monday.
A top World Health Organization official in Africa said last week that Uganda’s Ebola outbreak was “rapidly evolving,” describing a challenging situation for health workers.
Ugandan health authorities have...
Source: TIME: Health - October 20, 2022 Category: Consumer Health News Authors: Rodney Muhumuza/AP Tags: Uncategorized Disease healthscienceclimate wire Source Type: news
The Virus Hunters Trying to Prevent the Next Pandemic
Nobody saw SARS-CoV-2 coming. In the early days of the pandemic, researchers were scrambling to collect samples from people who had mysteriously developed fevers, coughs, and breathing problems. Pretty soon, they realized that the disease-causing culprit was a new virus humans hadn’t seen before.
And the world, lacking a coordinated global response, was unprepared. Some countries acted quickly to develop tests for the novel coronavirus, while others with fewer resources were left behind. With a virus oblivious to national borders, and with travel between countries and continents more common than it had been in previo...
Source: TIME: Health - August 1, 2022 Category: Consumer Health News Authors: Alice Park and Video by Andrew D. Johnson Tags: Uncategorized Disease Frontiers of Medicine 2022 healthscienceclimate Source Type: news
Antimicrobial Resistance Calls for Brainpower of a Space Agency and Campaigning Zeal of an NGO
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Source: IPS Inter Press Service - Health - November 17, 2021 Category: International Medicine & Public Health Authors: External Source Tags: Global Headlines Health Source Type: news
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
NEW BRUNSWICK, N.J., July 1, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted today to bioRxiv. “Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help prot...
Source: Johnson and Johnson - July 1, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson & Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson & Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participants ...
Source: Johnson and Johnson - April 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents
New Brunswick, NJ (April 2, 2021) – Johnson & Johnson (the Company) has begun vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. “The COVID-19 pandemic has had a profound impact on adolescents, not just with the complications of the disease, but with their education, mental health, and wellbeing,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “It is vital that we develop vaccines for everyone, everywher...
Source: Johnson and Johnson - April 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Another Covid-19 Threat: Health Care Workers Under Attack
A healthcare worker at a testing facility collects samples for the coronavirus at Mimar Sinan State Hospital, Buyukcekmece district in Istanbul, Turkey. Credit: UNDP Turkey/Levent KuluBy Joe Amon and Christina WillePHILADELPHIA, US, Mar 3 2021 (IPS) In the first months of the COVID-19 pandemic, at a certain hour of the evening, people in cities around the world opened their windows or stood on their rooftops and banged pots and rang bells. As the coronavirus spread and the number of deaths mounted, it was a moment for people distancing themselves from others to show solidarity and appreciation for the heroic work of health...
Source: IPS Inter Press Service - Health - March 3, 2021 Category: International Medicine & Public Health Authors: Joe Amon and Christina Wille Tags: Global Headlines Health TerraViva United Nations Source Type: news
Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.
NEW BRUNSWICK, N.J., February 28, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). “For more than 130 years, Johnson & Johnson has come to the aid of people during times of crisis, and we believe today’s re...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Source Type: news
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
NEW BRUNSWICK, N.J., February 27, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection against ...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
NIH Director Francis Collins Is Fighting This Coronavirus While Preparing for the Next One
In May 2020, Dr. Francis Collins, the longtime head of the National Institutes of Health (NIH), was called to the White House to meet with Jared Kushner, the then President’s son-in-law and adviser, and Dr. Deborah Birx, the head of the White House Coronavirus Task Force. A few weeks earlier, Congress had given the NIH $1.5 billion to try to speed up the process of developing new diagnostic tests for COVID-19, and the White House, which was dubious about increasing the rate of testing, wanted to know more about what the NIH was doing.
Collins is technically the boss of Dr. Anthony Fauci, but during the pandemic he ha...
Source: TIME: Health - February 4, 2021 Category: Consumer Health News Authors: Belinda Luscombe Tags: Uncategorized COVID-19 feature Magazine Source Type: news
Johnson & Johnson COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published in New England Journal of Medicine
January 13, 2021 -- Interim Phase 1/2a data were published today in the New England Journal of Medicine demonstrating that the Company’s single-dose investigational COVID-19 vaccine candidate (JNJ-78436735) – being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson – provided an immune response that lasted for at least 71 days, the duration of time measured in this study in participants aged 18-55 years. A preview of part of these interim data was posted on medRxiv in September 2020.The Phase 1/2a interim analysis showed that the Company’s COVID-19 vaccine candidate induced an immune respons...
Source: Johnson and Johnson - January 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Why Africa ’s COVID-19 Outbreak Hasn’t Been as Bad as Everyone Feared
When COVID-19 initially blazed through Asia, Europe and then the United States, global public health experts worried that it could be catastrophic for Africa, with its crowded cities, poorly funded health sector and lack of testing facilities. The U.N. Economic Commission for Africa in April predicted up to 300,000 deaths this year if the virus couldn’t be contained on the continent. Yet it was the U.S, with its superior health system, that hit that grim milestone first, and so far, Africa has been largely spared the worst of the devastation experienced by the rest of the world. As of Dec. 29, the Africa Centres for ...
Source: TIME: Health - December 30, 2020 Category: Consumer Health News Authors: Aryn Baker Tags: Uncategorized COVID-19 Londontime Source Type: news
Top Global Health Moments of 2020
By The Editorial Team,
IntraHealth International
Community Health Nurse Olivia Yeboah thoroughly washes her hands at the Akropong Clinic in Ghana. Photo by Emmanuel Attramah, PMI Impact Malaria/US President ' s Malaria Initiative.December 17, 2020If we wanted to, we could list a COVID-19 moment for every month of 2020. We all know that the onset of the coronavirus pandemic—first in China and then worldwide—overwhelmed news coverage this year. And with good reason. It’s the first large-scale global pandemic in 100 years. At the time this article was pu...
Source: IntraHealth International - December 17, 2020 Category: International Medicine & Public Health Authors: kseaton Tags: HIV & AIDS COVID-19 Nutrition Policy Advocacy Health Workforce Systems Nursing Midwifery 2020 Health Workers Source Type: news
How COVID-19 Catalysed Digital Health Trends
Coronavirus has shattered our world and changed nearly all aspects of our lives. It has also changed our relationship to healthcare. It is slowly becoming a cliché to say that COVID-19 has catalysed healthcare trends – but nevertheless, it’s true. Everyone in the world has seen what devastating impact healthcare can have on our daily lives and how underfunded healthcare systems depend on the heroic frontline workers, who are holding the walls from falling apart.
The windfall of the era of digital health is unquestionable, but it has always been. The hurdle was the adoption of these changes, for they posed infrastru...
Source: The Medical Futurist - November 19, 2020 Category: Information Technology Authors: Judit Kuszkó Tags: Forecast Lifestyle medicine Artificial Intelligence in Medicine Digital Health Research E-Patients Future of Medicine Future of Pharma Healthcare Design Healthcare Policy Medical Education AI MIT covid19 Source Type: blogs
COMMENTARY: The Sinatra Doctrine Confronts a Global Consensus
A photo-collage. Credit: Peter Costantini.By Peter CostantiniSEATTLE, Oct 23 2020 (IPS) By late September, the COVID-19 pandemic in the United States had claimed 200,000 lives. That’s equivalent to a slightly higher toll than the 418,500 United States deaths in World War II, adjusted for relative population and duration. [See note below.]
With four percent of the world’s population, the U.S. has suffered 20 percent of global COVID-19 deaths.
Tragically, most of these deaths need never have happened. They were caused primarily by the public-health equivalent of friendly fire: massive malpractice and deception by the Don...
Source: IPS Inter Press Service - Health - October 23, 2020 Category: International Medicine & Public Health Authors: Peter Costantini Tags: Global Geopolitics Global Governance Headlines Health TerraViva United Nations Source Type: news
